Hardik Chandasana

8PUBLICATIONS
5CO-AUTHORS
Pharmaceutical delivery technologiesMajor global burdens of diseasePharmacogenomicsAdolescent healthInfant and child health
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Sep 05, 2024
A Model-Based Approach Supporting Abacavir/Dolutegravir/Lamivudine Fixed-Dose Combination Approval in Children Living with HIV-1.

Hardik Chandasana, Ann M Buchanan, Michael McKenna

|Jul 17, 2024
Integrated Population Exposure-Response of Dolutegravir in HIV-1 Supports Bridging of Clinical Response Influenced by Relevant Intrinsic and Extrinsic Patient Characteristics.

Hardik Chandasana, Mark Bush, Cindy Vavro

|Jul 16, 2024
Population Pharmacokinetic Analysis of Dolutegravir in Treatment-Experienced Adults Living with HIV-1.

Hardik Chandasana, Mark Bush, Mounir Ait-Khaled

|Jul 03, 2024
Population Pharmacokinetic Modeling of Abacavir/Dolutegravir/Lamivudine to Support a Fixed-Dose Combination in Children with HIV-1.

Hardik Chandasana, Sven C van Dijkman, Rashmi Mehta

|Jun 27, 2024
Dosing Cefazolin for Surgical Site Infection Prophylaxis in Adolescent Idiopathic Scoliosis Surgery: Intermittent Bolus or Continuous Infusion?-A Pilot Study.

Yichao Yu, F Cole Dooley, Anna Woods

|Apr 08, 2024
Population pharmacokinetic modeling of dolutegravir/lamivudine to support a once-daily fixed-dose combination regimen in virologically suppressed adults living with HIV-1.

Hardik Chandasana, Rajendra Singh, Kimberly Adkison

Pageof 2

Frequent Collaborators

1 joint publications

Teodora Pene Dumitrescu

1 joint publications

F Cole Dooley

1 joint publications

Christoph N Seubert

1 joint publications

Mark Bush